$44.48
4.34% today
Nasdaq, Apr 04, 09:48 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$44.44
+5.78 14.95% 1M
+0.07 0.16% 6M
+5.84 15.13% YTD
+16.79 60.72% 1Y
+19.53 78.40% 3Y
+37.72 561.31% 5Y
+32.74 279.83% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-2.06 4.43%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Market capitalization $2.85b
Enterprise Value $2.45b
P/E (TTM) P/E ratio 11.06
EV/FCF (TTM) EV/FCF 13.38
EV/Sales (TTM) EV/Sales 5.63
P/S ratio (TTM) P/S ratio 6.57
P/B ratio (TTM) P/B ratio 4.20
Revenue growth (TTM) Revenue growth 624.06%
Revenue (TTM) Revenue $434.43m
EBIT (operating result TTM) EBIT $252.84m
Free Cash Flow (TTM) Free Cash Flow $182.80m
Cash position $418.91m
EPS (TTM) EPS $4.21
P/E forward negative
P/S forward 31.15
EV/Sales forward 26.70
Short interest 8.47%
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
434 434
624% 624%
100%
- Direct Costs 2.96 2.96
11% 11%
1%
431 431
661% 661%
99%
- Selling and Administrative Expenses 38 38
40% 40%
9%
- Research and Development Expense 138 138
15% 15%
32%
256 256
383% 383%
59%
- Depreciation and Amortization 2.96 2.96
11% 11%
1%
EBIT (Operating Income) EBIT 253 253
370% 370%
58%
Net Profit 275 275
449% 449%
63%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Accesswire
17 days ago
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most ...
Positive
Seeking Alpha
24 days ago
Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financiall...
Positive
Investors Business Daily
25 days ago
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily.
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today